Abstract Details

Title Risk of Developing Dementia in Essential Tremor

Topic Movement Disorders

Presentation(s) S53 - (-)

Poster/Presentation
Number 004

Objective

Background Previous population studies in the elderly have suggested that patients with tremor might be at higher risk for incident dementia when followed longitudinally.

Design/Methods Subjects without dementia or a neurodegenerative movement disorder at study entry, and who had at least one follow-up visit, were selected from the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) database. The incidence of dementia in subjects with ET was compared to that of Controls using Cox regression.

Results There were 90 subjects with ET and 432 subjects without ET. The proportion of women was lower in the ET group (44% versus 70%). Age at study entry ranged from 45 to 100 years. Mean age was not substantially higher in the ET group (79.9 years vs. 77.1 for controls). ApoE genotype was known for 58 subjects in the ET group and 250 subjects in the Control group. The proportion of ApoE ?4 carriers was not substantially different in the ET group (19% vs. 25%). Age at ET onset ranged from 0 to 90 years (mean 67, SD 19), and the duration of ET at study entry ranged from 0 to 72 years (mean 12, SD 18). The incidence of dementia was not higher in the ET group than in the Control group. The incidence of dementia within 5 years of study entry was 11% for both ET and Control groups (95% CI 4% to 17% for ET, and 8% to 14% for Control). The hazard ratio for the association between ET and dementia was 0.97 (95% CI 0.50 to 1.9). Adjustment for age, sex, and e4 status did not increase the hazard ratio for the association between ET and dementia.

Conclusions ET is not associated with increased risk of dementia in this longitudinal aging study.

Authors/Disclosures
Holly A. Shill, MD, FAAN (Barrow Neurology Clinics) PRESENTER	Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage Biogen. Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for KeifeRx. Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Praxis Precision Medicine. Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Fasikl Inc. Dr. Shill has received personal compensation in the range of $0-$499 for serving as a Consultant for Boston Scientific. Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe Pharma America.
Joseph Hentz (Mayo Clinic)	No disclosure on file
Christine Belden	Christine Belden has nothing to disclose.
	No disclosure on file
	No disclosure on file
Luis Jacinto	No disclosure on file
Marwan N. Sabbagh, MD, FAAN (Barrow Neurological Institute)	Dr. Sabbagh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genetech=Roche. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Sabbagh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Synaptogenix. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant Health. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Anavex. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cognito Therapeutics. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for CervoMed. Dr. Sabbagh has stock in Neurotau. Dr. Sabbagh has stock in Seq Biomarque. Dr. Sabbagh has stock in uMethod Health. Dr. Sabbagh has stock in Athira. Dr. Sabbagh has stock in Lighthouse Pharmaceuticals. Dr. Sabbagh has stock in Alzheon. The institution of Dr. Sabbagh has received research support from NIH. The institution of Dr. Sabbagh has received research support from ADDF.
John N. Caviness, MD, FAAN (Mayo Clinic)	Dr. Caviness has nothing to disclose.
Thomas Beach (Banner Sun Health Research Institute)	Thomas Beach has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vivid Genomics. Thomas Beach has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche Diagnostics. The institution of Thomas Beach has received research support from National Institutes of Health. The institution of Thomas Beach has received research support from Michael J Fox Foundation . The institution of Thomas Beach has received research support from State of Arizona.
Charles H. Adler, MD, PhD, FAAN (Mayo Clinic Arizona)	Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avion. Dr. Adler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for CND Life Sci. Dr. Adler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz. Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Precon. Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. The institution of Dr. Adler has received research support from NIH. The institution of Dr. Adler has received research support from Michael J. Fox Foundation. The institution of Dr. Adler has received research support from Arizona Biomedical Research Commission. Dr. Adler has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��